Listed

Arbutus Biopharma Corp: Form 10-Q for the period ended Jun 30, 2016

Filed with the SEC on Aug 4, 2016 and accepted by EDGAR at Aug 4, 2016, 17:21 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-04-01 to 2016-06-30$309.0kus-gaap:Revenues
Revenue6 months2016-01-01 to 2016-06-30$912.0kus-gaap:Revenues
Research and development3 months2016-04-01 to 2016-06-30$15.2mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2016-01-01 to 2016-06-30$28.4mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2016-04-01 to 2016-06-30−$195.2mus-gaap:OperatingIncomeLoss
Operating income6 months2016-01-01 to 2016-06-30−$215.2mus-gaap:OperatingIncomeLoss
Income tax3 months2016-04-01 to 2016-06-30−$64.9mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2016-01-01 to 2016-06-30−$64.9mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2016-04-01 to 2016-06-30−$130.0mus-gaap:NetIncomeLoss
Net income6 months2016-01-01 to 2016-06-30−$145.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-04-01 to 2016-06-30−$2.47us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2016-01-01 to 2016-06-30−$2.80us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2016-04-01 to 2016-06-30−$16.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Operating cash flow6 months2016-01-01 to 2016-06-30−$28.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2016-04-01 to 2016-06-30$954.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Capital expenditure6 months2016-01-01 to 2016-06-30$1.2mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2016-06-30$43.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-06-30$168.1mus-gaap:AssetsCurrent
Total assetsAt period end2016-06-30$530.9mus-gaap:Assets
Current liabilitiesAt period end2016-06-30$10.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-06-30$99.5mus-gaap:Liabilities
Shareholders' equityAt period end2016-06-30$431.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001628280-16-018534. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.